{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 3 of 81', 'Signature of principal investigator', 'The signatory agrees to the content of the final clinical study protocol as presented.', 'Name:', 'Affiliation:', 'Date:', 'Signature:', \"Signed copies of this signature page are stored in the sponsor's study file and in the respective\", \"center's investigator site file.\", 'In the protocol document, this page may remain unsigned.']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 4 of 81', '2.', 'Synopsis', 'Title', 'A randomized parallel-group, placebo-controlled, double-blind, multi-center', 'trial to evaluate the efficacy and safety of the oral sGC stimulator vericiguat to', 'improve physical functioning in activities of daily living in patients with heart', 'failure and preserved ejection fraction (HFpEF)', 'Short title', 'Patient-reported outcomes in vericiguat-treated patients with HFpEF', 'Acronym', 'VITALITY-HFpEF', 'Clinical study phase', 'Phase IIb', 'Study objectives', 'Primary objectives:', 'To evaluate the efficacy of vericiguat 10 mg in comparison to placebo on', 'improving physical functioning from baseline to week 24.', 'To evaluate the efficacy of vericiguat 15 mg in comparison to placebo on', 'improving physical functioning from baseline to week 24.', 'To evaluate the safety and tolerability of vericiguat.', 'Secondary objectives:', 'To evaluate the efficacy of vericiguat 10 mg in comparison to placebo on', 'improving distance traveled on a 6-minute walk test (6MWT) from', 'baseline to week 24', 'To evaluate the efficacy of vericiguat 15 mg in comparison to placebo on', 'improving distance traveled on a 6 MWT test from baseline to week 24.', 'To evaluate the efficacy of vericiguat 10 mg in comparison to placebo in', 'increasing the proportion of patients with Kansas City Cardiomyopathy', 'Questionnaire (KCCQ) physical limitation score (PLS) improvement', 'from baseline by >5 points at 24 weeks and other thresholds (e.g. >3, >7,', '>10, >15, >20), and the proportions with these improvements in the other', 'KCCQ domains; overall symptom score (OSS), clinical summary score', '(CSS), total symptom score (TSS) and symptom frequency score (SFS).', 'To evaluate the efficacy of vericiguat 15 mg in comparison to placebo in', 'increasing the proportion of patients with KCCQ PLS improvement from', 'baseline by >5 points at 24 weeks and other thresholds (e.g. >3, >7, >10,', '>15, >20), and the proportions with these improvements in the other', 'KCCQ domains OSS, CSS, TSS and SFS.', 'To evaluate the efficacy of vericiguat 10 mg in comparison to placebo in', 'decreasing the proportion of patients with KCCQ PLS decline from', 'baseline by >5 points at 24 weeks and the proportions with decline in the', 'other KCCQ domains OSS, CSS, TSS and SFS.', 'To evaluate the efficacy of vericiguat 15 mg in comparison to placebo in', 'decreasing the proportion of patients with KCCQ PLS decline from', 'baseline by >5 points at 24 weeks and the proportions with decline in the', 'other KCCQ domains OSS, CSS, TSS and SFS.']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 5 of 81', 'Other objectives:', 'To evaluate the efficacy of vericiguat 15 mg and the efficacy of', 'vericiguat 10 mg in comparison to placebo on improving', 'Symptom frequency as measured by the KCCQ SFS', 'Other patient-reported outcomes such as the generic health-related', 'quality of life measure EuroQoL five dimensions five levels', 'questionnaire (EQ-5D-5L) and the Fried-based frailty score', 'New York Heart association (NYHA) class', 'Laboratory variables such as N-terminal pro-brain natriuretic', 'peptide (NT-proBNP) from baseline to 24 weeks', 'To collect and summarize death including cardiovascular death, and CV', 'hospitalizations including heart failure hospitalizations, myocardial', 'infarction and stroke, and outpatient HF events.', 'To analyze the cumulative distribution function of KCCQ PLS, OSS,', 'CSS, TSS and SFS change from baseline at 24 weeks', 'To evaluate pharmacokinetics of vericiguat in patients with HFpEF.', 'To evaluate the concentration-QTc relationship of vericiguat at the 15 mg', 'dose level.', 'Optional pharmacogenetic research: To explore the relationship between', 'genetic variation and clinical characteristics of patients, independent and', 'dependent of the treatment administered. Variations across the human', 'genome may be analyzed for association with clinical data collected in', 'this study.', 'To evaluate further biomarkers to investigate the drug (i.e. mode-of-', 'action-related effect and/or safety) and/or the mechanisms of the disease', 'Optional accelerometry substudy: To collect exploratory data by activity', 'tracking', 'Test drug', 'Vericiguat, BAY 1021189', 'Name of active ingredient', 'Vericiguat, BAY 1021189', 'Doses', '2.5 mg, 5 mg, 10 mg, 15 mg', 'Route of administration', 'Oral', 'Duration of treatment', '24 weeks', 'Reference drug', 'Placebo', 'Name of active ingredient', 'N/A', 'Doses', 'N/A', 'Route of administration', 'Oral', 'Duration of treatment', '24 weeks']\n\n###\n\n", "completion": "END"}